相似文献
1
Commentary: Let us ponder - Choosing between topical Nepafenac and topical steroids after cataract surgery.
Indian J Ophthalmol. 2022 Mar;70(3):812-813. doi: 10.4103/ijo.IJO_2782_21.
2
Prophylaxis of macular edema after cataract surgery in diabetic patients, topical Nepafenac versus intravitreal Ranibizumab.
Eur J Ophthalmol. 2022 Jan;32(1):205-212. doi: 10.1177/11206721211001275. Epub 2021 Mar 16.
3
Comparison of preoperative nepafenac (0.1%) and flurbiprofen (0.03%) eye drops in maintaining mydriasis during small incision cataract surgery in patients with senile cataract: A randomized, double-blind study.
Indian J Pharmacol. 2015 Sep-Oct;47(5):491-5. doi: 10.4103/0253-7613.165201.
4
0.1% Nepafenac reduces pain and increases patient comfort during cataract surgery.
Cont Lens Anterior Eye. 2018 Oct;41(5):448-451. doi: 10.1016/j.clae.2018.05.003. Epub 2018 May 26.
5
Comparison of the Effect of Diclofenac 0.1% and Nepafenac 0.1% on Aqueous Flare in Patients Undergoing Cataract Surgery: A Prospective Randomized Study.
Curr Eye Res. 2020 Sep;45(9):1089-1093. doi: 10.1080/02713683.2020.1725061. Epub 2020 Feb 4.
6
How does nepafenac affect the choroidal thickness after uneventful cataract surgery?
Eur J Ophthalmol. 2021 Sep;31(5):2319-2328. doi: 10.1177/1120672120976041. Epub 2020 Nov 29.
7
Ocular permeation and inhibition of retinal inflammation: an examination of data and expert opinion on the clinical utility of nepafenac.
Curr Med Res Opin. 2006 Feb;22(2):397-404. doi: 10.1185/030079906X89775.
8
Comparison of the efficacy and patients' tolerability of Nepafenac and Ketorolac in the treatment of ocular inflammation following cataract surgery: A meta-analysis of randomized controlled trials.
PLoS One. 2017 Mar 2;12(3):e0173254. doi: 10.1371/journal.pone.0173254. eCollection 2017.
9
Cystoid and diabetic macular edema treated with nepafenac 0.1%.
J Ocul Pharmacol Ther. 2007 Dec;23(6):585-90. doi: 10.1089/jop.2007.0062.
10
Nepafenac 0.3% after Cataract Surgery in Patients with Diabetic Retinopathy: Results of 2 Randomized Phase 3 Studies.
Ophthalmology. 2017 Jun;124(6):776-785. doi: 10.1016/j.ophtha.2017.01.036. Epub 2017 Mar 6.
本文引用的文献
1
Comparison of once daily dose of 0.3% nepafenac alone and three times dose of 0.1% nepafenac alone in pain and inflammation control after phacoemulsification.
Indian J Ophthalmol. 2022 Mar;70(3):807-812. doi: 10.4103/ijo.IJO_2401_21.
2
Comparison between 0.1% Nepafenac and 1% Prednisolone Eye Drop in Postoperative Management Following Micro-incisional Cataract Surgery.
Korean J Ophthalmol. 2021 Jun;35(3):188-197. doi: 10.3341/kjo.2020.0135. Epub 2021 Jun 4.
3
Management of macular oedema in diabetic patients undergoing cataract surgery.
Curr Opin Ophthalmol. 2017 Jan;28(1):23-28. doi: 10.1097/ICU.0000000000000328.
4
Risk Factors and Incidence of Macular Edema after Cataract Surgery: A Database Study of 81984 Eyes.
Ophthalmology. 2016 Feb;123(2):316-323. doi: 10.1016/j.ophtha.2015.10.001. Epub 2015 Dec 8.
5
Topical nonsteroidal anti-inflammatory drugs for ophthalmic use: a safety review.
Drug Saf. 2002;25(4):233-50. doi: 10.2165/00002018-200225040-00002.
6
Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy.
Inflammation. 2000 Aug;24(4):357-70. doi: 10.1023/a:1007049015148.
7
Nonsteroidal anti-inflammatory drugs and cataract surgery.
Arch Ophthalmol. 1994 Jul;112(7):891-4. doi: 10.1001/archopht.1994.01090190039018.
Zotero 插件